H2FPEF Score Calculation and Interpretation
The H2FPEF score is a 0-9 point diagnostic tool that uses six readily accessible clinical variables to estimate the probability of HFpEF in patients with dyspnea and preserved ejection fraction, with scores ≥6 indicating high likelihood (>95%), scores <2 indicating low likelihood, and scores 2-5 requiring further hemodynamic testing for confirmation. 1, 2, 3
Score Components and Point Assignment
The H2FPEF acronym represents six weighted variables 1, 2, 3, 4:
- H (Heavy): BMI >30 kg/m² = 2 points 3, 4
- H (Hypertension): Treatment with ≥2 antihypertensive medications = 1 point 3, 4
- F (Atrial Fibrillation): Paroxysmal or persistent = 3 points 3, 4
- P (Pulmonary hypertension): Echocardiographic PA systolic pressure >35 mm Hg = 1 point 3, 4
- E (Elder): Age >60 years = 1 point 3, 4
- F (Filling pressures): Echocardiographic E/e' ratio >9 = 1 point 3, 4
Score Interpretation and Clinical Action
High Probability (Score ≥6 points)
- Indicates >95% likelihood of HFpEF 1, 2, 4
- Specificity of 97% and positive predictive value of 94% 5
- Proceed directly with HFpEF treatment without additional invasive testing 1, 2
Low Probability (Score 0-1 points)
- Pursue alternative diagnoses for dyspnea 1, 2, 6
- Sensitivity of 97% and negative predictive value of 93% for ruling out HFpEF 5
- Consider noncardiac causes including pulmonary disease, anemia, obesity-related dyspnea, or deconditioning 3
Intermediate Probability (Score 2-5 points)
- Requires further diagnostic evaluation with either exercise stress echocardiography or invasive hemodynamic testing 1, 2, 6
- Exercise PCWP ≥25 mm Hg confirms HFpEF diagnosis 6
- Exercise PA systolic pressure ≥45 mm Hg provides 96% sensitivity and 95% specificity for HFpEF 6
- Alternative pragmatic approach: initiate therapeutic trial of guideline-directed medical therapy (diuretics plus SGLT2 inhibitor) and assess symptomatic response 3
Diagnostic Performance
The H2FPEF score demonstrates excellent discrimination with a c-statistic of 0.841 (95% CI: 1.74-2.30; P<0.0001) 1, 2, 4. Each 1-point increase in score doubles the odds of HFpEF (odds ratio 1.98) 1, 2, 4. The score was validated against gold-standard invasive exercise hemodynamic measurements 3, 7.
Critical Caveats and Limitations
When to Override a Low Score
A low H2FPEF score should NOT exclude HFpEF diagnosis when clinical suspicion remains high based on symptoms, signs, and elevated natriuretic peptides 3, 4. The pretest clinical assessment guides the diagnostic utility of the scoring system 3.
Special Populations with Reduced Accuracy
- Patients with atrial fibrillation: The H2FPEF score shows only moderate accuracy (AUC 0.707) with 69% sensitivity and 66% specificity in AF patients 8
- Obese patients: May have falsely low natriuretic peptides despite elevated filling pressures, though the H2FPEF score accounts for obesity as a weighted variable 3
- Elderly patients: Clinical signs become difficult to interpret, making objective testing more critical 9
Early-Stage HFpEF
In patients with normal resting hemodynamics but exertional symptoms (particularly older women with hypertension, obesity, diabetes, or CKD), resting parameters may be completely normal despite symptomatic HFpEF 6. These patients require exercise testing when scores are intermediate 6.
Integration with Other Diagnostic Criteria
The H2FPEF score should be used within the framework of the Universal Definition of Heart Failure, which requires symptoms/signs PLUS either elevated natriuretic peptides (NT-proBNP >125 pg/mL or BNP >35 pg/mL) OR objective evidence of cardiogenic congestion 1, 2, 9. The score does not include natriuretic peptides, which is both a strength (simplicity) and limitation (may miss cases with elevated biomarkers but lower clinical scores) 3.
Prognostic Value
Beyond diagnosis, the H2FPEF score predicts cardiovascular outcomes in confirmed HFpEF patients 10. Each 1-point increase independently predicts cardiovascular events (HR 1.179) and HF-related events (HR 1.288), with a cutoff score of 5.5 identifying higher-risk patients 10.